A $93 billion plunge in Novo Nordisk A/S shares has provided the latest blow to Europe’s largest listed companies, which have ...

Results for its new CagriSema drug, while promising, fell below expectations, sending shares of the pharmaceutical giant down ...

The Food and Drug Administration expanded the approval of weight loss drug Zepbound to treat obstructive sleep apnea in ...

Novo Nordisk (NVO) increased valuation gap with Eli Lilly (LLY) after its Phase 3 data for next-gen weight loss drug ...

The weight-loss biotech Viking Therapeutics ( VKTX 1.83%) saw its stock get absolutely slammed on Dec. 18, falling 18% as a ...

Novo Nordisk ’s big bet to improve on the success of its weight-loss drug franchise hit a stumbling block Friday, wiping out ...

Recent health news highlights include a landmark ruling by the Inter-American Court of Human Rights concerning abortion ...

A new study put Eli Lilly's Zepbound and Novo Nordisk's Wegovy to the test. Here's which one will help you lose more weight.

U.S. stocks rose to turn what would have been one of the market’s worst weeks of the year into just a pretty bad one ...

Health-care companies rose, as health insurers and other "middle men" recouped some of their recent losses. UnitedHealth Group, which has become the center of a public debate about health-care policy ...

The Dow, S&P 500, and Nasdaq rose as the stock market reacted to a potential federal government shutdown, despite a cool PCE inflation report.

Employees of the coffee chain launched a five-day action in Chicago, Los Angeles and Seattle after the union called for a strike. Eli Lilly is now comfortably ahead of Novo Nordisk in the race to ...